We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Vesanoid, First Retinoid to Receive a Cancer Indication,Is Approved for Treatment of APL

Jan 1, 1996
Volume: 
5
Issue: 
1

NUTLEY, NJ--Vesanoid (treti-noin, all-trans-retinoic acid) has
become the first retinoid to receive a cancer treatment indication
from the US Food and Drug Administration. The new agent, from
Hoffmann-La Roche, is indicated for induction of remission in
patients with acute promyelocytic leukemia (APL) who are refractory
to or have relapsed from anthracycline chemotherapy, or for whom
anthracy-cline chemotherapy is contraindicated.

Vesanoid is for induction of remission only, and it should be
followed by an accepted form of remission consolidation and/or
maintenance therapy.

In APL patients achieving complete remission, the agent produces
an initial maturation of the primitive promye-locytes derived
from the leukemic clone, followed by marrow repopulation by normal,
polyclonal hematopoietic cells.

In an open-label, uncontrolled study from Memorial Sloan-Kettering
Cancer Center and two cohorts of compassionate cases treated by
multiple investigators under the auspices of the NCI, complete
remissions among previously treated patients ranged from 50% to
80%, compared with rates of 30% to 50% previously reported for
cytotoxic chemotherapy of APL in relapse.

Median survival for Vesanoid-treated patients ranged from 5.8
to 10.8 months, compared with less than 6 months in studies of
cytotoxic chemotherapy.

In clinical trials, about 25% of Vesanoid-treated patients experienced
retinoic acid-APL (RA-APL) syndrome, which is characterized by
fever, dyspnea, weight gain, radiographic pulmonary infiltrates,
and pleural or pericardial effusions. High-dose steroids given
at the first suspicion of the syndrome appear to reduce morbidity
and mortality.

During Vesanoid treatment, about 40% of patients will develop
rapidly evolving leukocytosis. Patients who present with leukocytosis
at diagnosis have an increased risk of a further rapid increase
in WBC counts, which is associated with a higher risk of life-threatening
complications. In these cases, adding full-dose chemotherapy to
the Vesanoid regimen may be recommended.

Pages

  • 1
  • 2
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.